Coherus Oncology formally introduces non-proprietary name: tagmokitug--Publication shows picomolar affinity for CCR8 with no off-target binding ...

Dream in Gold Afterparty Skybar Affinity Nightlife once again hosts a post-show party in WeHo paying homage to the brightest ...

This important study introduces a new biology-informed strategy for deep learning models aiming to predict mutational effects in antibody sequences. It provides solid evidence that separating ...

"Tequila is artier than vodka. So, for the purposes of this interview, vodka is Live Nation and tequila is City Winery," says ...

Brown is launching an initiative to support healing and recovery after the Dec. 13 mass shooting in Barus and Holley, ...

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

The Atlanta Falcons have fired Raheem Morris, and the Cleveland Browns have fired Kevin Stefanski. Those teams join the New ...

In other moves across the league, the Browns fired Kevin Stefanski, the Cardinals let go of Jonathan Gannon, and the Falcons ...

The Atlanta Falcons have fired Raheem Morris, and the Cleveland Browns have fired Kevin Stefanski. Those teams join the New ...

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 ...

Investing.com -- Coherus BioSciences Inc (NASDAQ:CHRS) stock rose 5.8% on Monday following the publication of research supporting the potential of its investigational cancer treatment tagmokitug.